To Evaluate the Tolerance, pd, and pk of Lanthanum Polystyrene-sulfonate Powder in a Phase Ib/ IIa Clinical Trial in Patients With ESRD-HD Hyperphosphatemia With Multi-center, Multi-dose, Give the Drug Multiple Time

The aim of the study is:
To evaluate the tolerance of lanthanum polystyrene sulfonate powder in patients with end-stage renal disease (ESRD-HD) hyperphosphatemia with multiple doses and multiple doses； To evaluate the pharmacodynamics of lanthanum polystyrene sulfonate powder in hyperphosphatemia patients with end-stage renal disease on hemodialysis (ESRD-HD); To evaluate the pharmacokinetics of lanthanum polystyrene sulfonate powder in patients with end-stage renal disease (ESRD-HD) hyperphosphatemia after multi-dose and multiple administration.

Start Date21 Oct 2020

Sponsor / Collaborator

Liaoning Nuokang Bio-Pharmaceutical Co. Ltd.

[+1]

NCT03451019

/ CompletedPhase 4IIT

Effect of Lanthanum Carbonate and Sevelamer Hydrochloride on Gastrointestinal Calcium Absorption in Patients With Moderate to Advanced Chronic Kidney Disease

Sevelamer hydrochloride (SE) can increase intestinal calcium absorption in contrast to lanthanum carbonate (LA). Study compared effect of LA and SE on serum and urine phosphate and calcium, and hormones regulating mineral-bone metabolism.

Start Date01 Mar 2018

Sponsor / Collaborator

Medical University of Lodz

[+1]

JPRN-UMIN000030503

/ SuspendedNot ApplicableIIT

The study about the effect of combination therapy of active form of vitamin D and lanthanum carbonate for serum concentration of FGF23 - CVD-LAF study

Start Date20 Jan 2018

Sponsor / Collaborator

Fujita Health University

100 Clinical Results associated with Lanthanum carbonate

100 Translational Medicine associated with Lanthanum carbonate

100 Patents (Medical) associated with Lanthanum carbonate

1,286

Literatures (Medical) associated with Lanthanum carbonate

01 Mar 2025·BIOLOGICAL TRACE ELEMENT RESEARCH

State-of-the-art Investigation on the Role of Indium, Terbium, Yttrium, and Lanthanum in Recurrent Pregnancy Loss

Article

Author: AlSheikh, Yazeed A ; Abudawood, Manal ; Tabassum, Hajera ; Alrashed, May ; Binhassan, Sarah ; Alrashoudi, Reem Hamoud ; Fatima, Yaqoot ; Fatima, Sabiha ; Ali, Mir Naiman

We aimed to explore the role of Indium (In), Terbium (Tb), Yttrium (Y), and Lanthanum (La) in the serum of women with recurrent pregnancy loss (RPL) and compare them to controls. Additionally, the study aimed to examine the relationship between REE levels and oxidative DNA damage, to identify potential risk factors contributing to RPL. This case-control study included 30 RPL cases and 30 controls with uncomplicated pregnancy. Inductively Coupled Plasma Mass Spectrometer was used to evaluate levels of In, Tb, Y, and La in the serum samples in both groups. The relationship between REE levels, Total Antioxidant Capacity (TAC), and DNA damage was studied by correlation analysis. There was a significant increase in levels of In, Tb, Y, and La in the serum of the RPL group in contrast to the control group (P < 0.001). Furthermore, a negative correlation was observed between increased Y, Tb, La, and TAC in RPL cases (significant at P < 0.05), indicative of weakened antioxidant defenses. Moreover, increased levels of Y, Tb, and La exhibited a positive correlation with the DNA damage marker, statistically significant at P < 0.05. These findings highlight the potential role of oxidative stress-induced DNA damage and metal intoxication in the development of RPL, underscoring the importance of further research to clarify underlying mechanisms and develop preventive strategies.

01 Mar 2025·JOURNAL OF MICROSCOPY

The photosensitive endoplasmic reticulum‐chloroplast contact site

Article

Author: Griffing, Lawrence R. ; Maynard, Sara N.

Abstract:

The endoplasmic reticulum (ER) forms contact sites with the chloroplast. Exposing contact sites that contain both the chloroplast and the ER to localised high‐fluence, wavelength specific, 405 nm violet light, hereinafter referred to as photostimulation, induces multiple, potentially interacting intra‐ and intercellular responses. The responses vary depending on the tissue type of the cell and the chloroplast. Photostimulating the ER‐chloroplast contact sites in growing epidermal cells of the hypocotyl of Arabidopsis thaliana, produces a wave of cytoplasmic ionic calcium that traverses the cell, spreading radially to other cells around the circumference of the hypocotyl. A transient ER stress accompanies the calcium wave. These responses occur in older epidermal cells (5–8 days post‐germination) with nonmotile chloroplasts tethered to the ER and the cell cortex but do not occur with motile or dividing chloroplasts. Dividing chloroplasts show a markedly different association with the ER, which forms a ring around the fission plane, similar to that of dividing mitochondria. Inhibition of calcium channels with lanthanum has no effect. Photostimulation of only the ER results in no ER stress and a calcium wave with a different spatiotemporal signature: delayed release and lower magnitude, with no accompanying ER stress response. Likewise, photostimulation of the chloroplast only, without the ER, produces no calcium wave or ER stress. General chloroplast photobleaching or restructuring caused by photostimulation is not the cause of this response; photostimulation with 488 nm of the same intensity and power as 405 nm photostimulation produces no change in cytosolic calcium levels. The pH of the ER decreases, indicating the involvement of ER ion transporters in the response. A wave of increased reactive oxygen species (ROS) in mitochondria and nuclei accompanies photostimulation. Together, these data support a model by which tethered ER‐chloroplast contact sites constitute a unique subcellular photosensitive region and are part of an ER‐mediated signalling network.Lay Abstract: The endoplasmic reticulum (ER) forms contact sites with the chloroplast. Shining violet (405 nm) light on the chloroplast with its associated ER produces a calcium wave through the cell that is communicated to other cells. This is correlated with a wave of transient denaturation of the luminal proteins of the ER (ER stress) and increased reactive oxygen species (ROS) in mitochondria. The wavelength dependence and precise cellular location of the light stimulation implies a novel way for plants to sense light. The movement of the response through the cell is consistent with the mediation of the response by a subcellular network, such as that formed by the ER.

01 Feb 2025·Kidney International Reports

A Targeted Release Capsule of Lanthanum Carbonate: a New Efficient Cheap Treatment for Primary Hyperoxalurias

Article

Author: Trouet, Dominique ; Elseviers, Monique ; De Causmaecker, Jan ; Uytterhoeven, Marc P ; Van Hoeck, Koen ; De Broe, Marc E ; De Brucker, Yannick ; Snelders, Erik D ; Van De Walle, Johan

Introduction:

Primary hyperoxaluria (PH) is a devastating disease in children and adults. Recently, a substantial progress in the treatment of this deadly disease has been made that consists of the introduction of the RNA inhibitors, lumasiran and nedosiran, which deplete the substrate for oxalate synthesis.

Methods:

Lanthanum carbonate (Lanth.Carb., La²[CO₃]³) is a powerful phosphate binder having a strong affinity to oxalate. Its use as such in PH is not relevant because patients with normal renal function develop a severe phosphate depletion without a clear effect on oxalate balance. Considering that the absorption of phosphate is in the early gastrointestinal (GI) tract and mainly in the distal part of the GI tract for oxalate, we developed a targeted release capsule (trc) containing 500 mg Lant.Carb. released in the distal part of the GI tract as proven by radiological investigations of the radiopaque trcLanth.Carb.

Results:

Four patients with PH and estimated glomerular filtration rate > 60 ml/min per 1.73 m² were treated with trcLanth.Carb., which turned out to decrease the urinary oxalate concentrations clearly < 0.51 mmol/24 h per 1.73 m²,45 mg/24 h per 1.73 m² (considered as upper limit of normal), after 2.5 months of treatment in 3 patients and 18 months in 1 patient. Calciuria remained normal or decreased slightly. Phosphaturia and phosphatemia remained normal and stable in all 4 cases.

Conclusion:

trcLanth.Carb. is a promising repurposed, efficient, nontoxic, and cheap drug, lacking serious side effects in the treatment of any type of PH in whatever place in the world. A randomized controlled trial supporting this proof-of-concept is the next step.

News (Medical) associated with Lanthanum carbonate

20 Dec 2024

·www.prnewswire.com

Chungnam National University Researchers Develop A Rapid Water Quality Monitoring Chip for Antibiotic Detection

DAEJEON, South Korea, Dec. 20, 2024 /PRNewswire/ -- Antimicrobial resistance (AMR) is a growing global health crisis because of microbes, such as bacteria, becoming resistant to antibiotics. A leading factor in this rise is the improper use and disposal of antibiotics in the environment. Effluents from wastewater treatment plants often contain various antibiotics including trimethoprim (TMP), which can harm ecosystems by disrupting microbial communities essential for nutrient cycling. In addition to contributing to AMR, TMP poses various health risks to humans through indirect exposure. Continue Reading Scientists developed a simple TMP detection device for on-site monitoring of contaminated wastewater using selenite-enriched lanthanum hydroxide electrode and polyimide-filter microfluidic channel. Traditional methods for TMP detection such as capillary electrophoresis and liquid chromatography with mass spectrometry, are often labor-intensive and time-consuming. Electrochemical (EC) methods can provide respite from these issues by offering exceptional sensitivity, real-time analytical capabilities and the potential for miniaturization. Professor Tae Yoon Lee and Dr. Natarajan Karikalan of Chungnam National University, Korea, have made a pioneering advancement in EC detection methods, that shows promise to revolutionize on-site testing for TMP in contaminated wastewater. They developed a disposable microfluidic lab-on-a-chip (LOC) EC sensor, μTMP-chip, designed for real-time TMP detection. "Efficient TMP monitoring in effluents is critical for effective control protocols. Hence, we aimed to enable in situ testing of water samples," explains Prof. Lee. Their paper was made available online on September 21, 2024 and was published in Volume 499 of Chemical Engineering Journal on November 1, 2024. The researchers designed the disposable chip by combining a special electrode made with lanthanum hydroxide and selenite, with a polyimide (PI) filter in a microfluidic channel. The analyses showed that the addition of selenite improved the electrode's ability to detect chemicals by allowing better charge flow. Additionally, the PI filter improved the μTMP-chip's real-time performance, while the efficiency dropped by 15 to 45% when the filter was removed. Additionally, the filter helped trap and isolate unwanted materials and prevented the risk of microbial growth, which could interfere with the sensor's function. The μTMP-chip sensor demonstrated impressive results in real-world testing, showing recovery rates of 94.3 % to 97.6 % in soil and water samples. These results, obtained through wireless testing, highlight the chip's potential for practical use in monitoring environmental samples. "Our current design may face challenges in detecting TMP in highly polluted environments with significant matrix interferences. However, we hope our research will inspire further exploration into developing affordable and efficient TMP detection chips," said Prof. Lee. The researchers believe that their innovative lab-on-a-chip design has the potential to improve the feasibility of on-site, real-time tracking of environmental contaminants leading to improved conservation of ecosystems and human health. Reference Title of original paper: Microfluidic sensor integrated with selenite-enriched lanthanum hydroxide and in situ filtration for the on-site detection of the antibiotic trimethoprim in environmental samples Journal: Chemical Engineering Journal DOI: 10.1016/j.cej.2024.155982 About the institute Website: Media Contact: Gaeun Kim +82 42-821-6239 [email protected] SOURCE Chungnam National University WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical Result

01 Jun 2024

·www.globenewswire.com

Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting

NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the publication of preclinical GD2-SADA data at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting, taking place May 31 through June 4, 2024, in Chicago, IL. The published abstract titled “Preclinical characterization of pretargeted radioimmunotherapy with GD2-SADA, a self-assembling and disassembling bispecific fusion protein” characterizes the binding properties of GD2-SADA across several GD2-expressing cell lines and lanthanide metal-DOTA complexes, while also demonstrating its anti-tumor efficacy when used with Lutetium 177 (Lu177)-DOTA in a two-step approach to pretargeted radioimmunotherapy (“PRIT”). In this analysis, GD2-SADA showed tight binding to cell lines expressing GD2, a glycolipid implicated in the malignant transformation of multiple solid tumors. GD2-SADA binding was significantly improved by a p53-derived domain that drives the self-assembly and disassembly (“SADA”) of GD2-SADA tetramers, which possess four distinct GD2-binding domains that cumulatively enhance binding. Previous studies have shown that the unbound GD2-SADA protein disassembles over time, facilitating clearance by the kidneys. “We believe that these data further validate GD2-SADA's promise as a novel targeted radioimmunotherapy and support the continued advancement of our SADA PRIT technology platform and clinical programs,” said Vignesh Rajah, MBBS, DCH, MRCP (UK), Chief Medical Officer. The analysis further demonstrated high-affinity binding of GD2-SADA to DOTA complexes chelated with lutetium and lanthanum, among other lanthanide metals. By contrast, GD2-SADA showed negligible binding to trace metal-DOTA complexes or empty DOTA, an important consideration for the targeted delivery of the radioactive payload in patients. “We are especially encouraged by the selective binding of GD2-SADA to lanthanide metal-DOTA complexes with current and emerging applications in the diagnosis and targeted treatment of solid tumors,” said Brian H. Santich, Ph.D., the lead author and co-inventor of the SADA PRIT technology platform. Taken together, the binding properties of the GD2-SADA protein provide a pharmacological basis for the robust and dose-responsive anti-tumor effects of GD2-SADA Lu177 PRIT in vivo, also presented in this seminal research. These findings have paved the way for the clinical development of GD2-SADA PRIT in adults and adolescents with GD2-positive tumors (NCT05130255). Y-mAbs will be available for comment at booth #35151 on the Exhibition Floor of McCormick Place. Researchers at MSK, including Dr. Nai-Kong Cheung, developed the SADA technology for radioimmunotherapy, which is exclusively licensed by MSK to Y-mAbs. Dr. Cheung has intellectual property rights and interests in the technology, and as a result of this licensing arrangement, MSK has institutional financial interests in the technology. About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (“SADA”) Pretargeted Radioimmunotherapy Platform (“PRIT”) and bispecific antibodies generated using the Y-BiClone platform. The Company’s broad and advanced product pipeline includes the anti-GD2 therapy DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy. Forward-Looking StatementsStatements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, statements about our business model, including financial outlook for 2023 and beyond, including estimated operating expenses, cash burn and DANYELZA product revenue and sufficiency of cash resources and related assumptions; implied and express statements regarding the future of the Company’s business, including with respect to expansion and its goals; the Company’s plans and strategies, development, commercialization and product distribution plans, including potential partnerships; expectations with respect to the Company’s products and product candidates, including potential territory and label expansion of DANYELZA and the potential market opportunity related thereto and potential benefits thereof, and the potential of the SADA Technology and potential benefits and applications thereof; statements with respect to DANYELZA as a growing commercial product and SADA as a differentiated radioimmunotherapy platform positioning the Company on a path to potentially transform the treatment paradigm for a variety of cancers and improve patients’ lives; expectations relating to key anticipated development milestones, including potential expansion of international commercialization efforts with respect to DANYELZA development efforts and the SADA Technology, including potential indications and applications, and the timing thereof; expectations with respect to current and future clinical and pre-clinical studies and the Company’s research and development programs, including with respect to timing and results; expectations related to the timing of the initiation and completion of regulatory submissions; additional product candidates and technologies; expectations regarding collaborations or strategic partnerships and the potential benefits thereof; expectations related to the use of cash and cash equivalents, and the need for, timing and amount of any future financing transaction; expectations with respect to the Company’s future financial performance; and other statements that are not historical facts. Words such as ‘‘anticipate,’’ ‘‘believe,’’ “contemplate,” ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘should,’’ ‘‘target,’’ “will”, ‘‘would’’, “guidance,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our product candidates and related technologies are novel approaches to cancer treatment that present significant challenges. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with the Company’s financial condition and need for additional capital; the risks that actual results of the Company’s restructuring plan and revised business plan will not be as expected; risks associated with the Company’s development work; cost and success of the Company’s product development activities and clinical trials; the risks of delay in the timing of the Company’s regulatory submissions or failure to receive approval of its drug candidates; the risks related to commercializing any approved pharmaceutical product including the rate and degree of market acceptance of product candidates; development of sales and marketing capabilities and risks associated with failure to obtain sufficient reimbursement for products; the risks related to the Company’s dependence on third parties including for conduct of clinical testing and product manufacture; the Company’s inability to enter into partnerships; the risks related to government regulation; risks related to market approval, risks associated with protection of the Company’s intellectual property rights; risks related to employee matters and managing growth; risks related to the Company’s common stock, risks associated with macroeconomic conditions, including the conflict between Russia and Ukraine and sanctions related thereto, the state of war between Israel and Hamas and the related risk of a larger regional conflict, inflation, increased interest rates, uncertain global credit and capital markets and disruptions in banking systems; and other risks and uncertainties affecting the Company including those described in the "Risk Factors" section included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 and future filings and reports by the Company. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. DANYELZA® and Y-mAbs® are registered trademarks of Y-mAbs Therapeutics, Inc. Investor Contact:Courtney DuganVP, Head of Investor Relationscdu@ymabs.com

ImmunotherapyLicense out/inASCODrug ApprovalClinical Study

02 Jan 2024

·www.businesswire.com

Natco Pharma Limited Completes Transition of DASH Pharmaceuticals into Natco Pharma USA, Furthering Strategic Presence in the United States

PARSIPPANY, N.J.--( BUSINESS WIRE )--Natco Pharma Limited, a research and development (R&D)-focused pharmaceutical company based in India, today announced that DASH Pharmaceuticals, a company that markets, sells, and distributes generic pharmaceutical products, has officially transitioned to Natco Pharma USA, the U.S. subsidiary of Natco Pharma. As of January 2, all products marketed by the company will transition to the Natco Pharma USA label, with no changes to the current NDC Numbers. Natco Pharma USA is led by Subba Rao Mente, Chief Executive Officer. Julie Trendowicz and Nick DiMaio, the former Executive Vice President and President of DASH, respectively, will assume the same roles under Natco Pharma USA. “ By acquiring DASH, Natco Pharma has gained a strategic presence in the United States, connecting us directly with our valued customers in this crucial market,” said Subba Rao Mente, Chief Executive Officer of Natco Pharma USA. “ This strategic move isn't just about growth; it's about bolstering our commitment to the U.S. pharmaceutical landscape.” Since 2007, Natco Pharma has been active in the US market, forging co-development and licensing partnerships with leading U.S. generic pharmaceutical companies. The company’s collaborative efforts have culminated in the successful development and launch of a range of first-to-market generics and complex formulations, including Lenalidomide Capsules, Glatiramer Acetate Pre-Filled Syringes, Liposomal Doxorubicin Vials, Oseltamivir Phosphate Capsules, Lanthanum Carbonate Chewable Tablets, Everolimus Tablets, and Lapatinib Tablets. These launches have firmly established Natco Pharma as a formidable and trustworthy entity in the U.S. generic pharmaceutical industry, laying the groundwork for a large-scale expansion into the U.S. With the establishment of Natco Pharma USA, the company hopes to continue to increase accessibility and affordability of its generic products. About Natco Pharma Limited Natco Pharma Limited (Natco Pharma) is an R&D-focused pharmaceutical company based in Hyderabad, India, with subsidiaries in North America, Latin America, Australia, and Southeast Asia. With nearly 4,500 employees worldwide, the company develops, manufactures, and markets Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs) with a focus on niche therapeutic areas and complex products. The company's products reach more than 40 countries globally through its own subsidiaries and partnerships, where Natco products are out-licensed to multinational companies and companies with strong local and regional presence in their respective geographies. About Natco Pharma USA Based in New Jersey, Natco Pharma USA is the U.S. Sales and Marketing company for all DASH products, as well as current, future and non-committed products developed and manufactured by Natco Pharma. The company's growing product catalog includes products across multiple therapeutic areas. Natco Pharma USA has various opportunities for collaborating, including a variety of profit-share and supply-chain initiatives such as Co-Development/Co-Ownership of ANDAs, Licensing of ANDAs, Acquisition of NDAs/ANDAs, and Authorized Generics. For more information, please visit www.natcopharmausa.com .

AcquisitionLicense out/in

100 Deals associated with Lanthanum carbonate

External Link

KEGG	Wiki	ATC	Drug Bank
D04667	Lanthanum carbonate	V03AE03	DB06792

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hyperphosphatemia	Austria	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Belgium	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Bulgaria	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Denmark	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Estonia	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Finland	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	France	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Hungary	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Iceland	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Ireland	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Italy	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Latvia	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Lithuania	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Luxembourg	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Malta	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Netherlands	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Norway	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Slovakia	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Slovenia	Takeda Pharmaceuticals International AG	01 Mar 2005
Hyperphosphatemia	Spain	Takeda Pharmaceuticals International AG	01 Mar 2005

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Kidney Diseases	Phase 3	Japan	Bayer AG	01 Jun 2010
Chronic Kidney Diseases	Phase 3	Japan	Shire Plc	01 Jun 2010
Chronic kidney disease, Stage V	Phase 3	United States	Shire Plc	05 Jan 2007
Chronic kidney disease, Stage V	Phase 3	Germany	Shire Plc	05 Jan 2007
Chronic kidney disease, Stage V	Phase 3	Puerto Rico	Shire Plc	05 Jan 2007
Chronic kidney disease, Stage V	Phase 3	United Kingdom	Shire Plc	05 Jan 2007
Calciphylaxis	Phase 1	United States	Shire Plc	01 Feb 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02209636 (Pubmed \| Kidney360)	Phase 4	Chronic Kidney Diseases serum phosphorus \| oxidative stress \| vascular dysfunction	54	Lanthanum carbonate	qglnrvirbi(eeqrwohuob) = hcgpghpzjl lywfiapcwh (danbpubbxd )	Negative	23 May 2024
				Placebo	qglnrvirbi(eeqrwohuob) = ngufvywsnj lywfiapcwh (danbpubbxd )
NCT03136705 (CTgov)	Phase 1	-	39	Lanthanum Carbonate+Nicotinamide (Lanthanum + Nicotinamide)	shnftjncsi(asvxjihigl) = gordczeluw ljrcfbxnny (pluvkjloqv, mipqirgfqc - dbllxrdilc) View more	-	23 Feb 2024
				Lanthanum Carbonate+Nicotinamide Placebo (Lanthanum + Nicotinamide Placebo)	shnftjncsi(asvxjihigl) = ofiqcodcio ljrcfbxnny (pluvkjloqv, fudmqkgpuq - qjwacmduve) View more
NCT02209636 (ASN ‘21 PO-0543, ASN2022)	Phase 4	Chronic Kidney Diseases	15	Lanthanum Carbonate	wjgcbtrabt(ahjmpxkwoq) = iszqpkkpwb tepcblanwh (etikcxjtzx )	Negative	05 Nov 2022
				Placebo	wjgcbtrabt(ahjmpxkwoq) = viillrnfjr tepcblanwh (etikcxjtzx )
NCT02209636 (ASN2021)	Phase 4	Chronic Kidney Diseases	15	Lanthanum Carbonate	dcbgkvgbvl(wcemfqtlgb) = ntltlbpbtu cutdlweutl (cjaysxkpnu )	Positive	27 Oct 2021
				Placebo	dcbgkvgbvl(wcemfqtlgb) = zdtyeczvqc cutdlweutl (cjaysxkpnu )
ASN2021	Not Applicable	Chronic Kidney Diseases	-	Calcium acetate	xwmijomzok(ohhwkgcwvc) = qnrlspflzo dlaghlsjpk (sjgabaiuox )	-	27 Oct 2021
				Ferric citrate	xwmijomzok(ohhwkgcwvc) = fdcfyepvmb dlaghlsjpk (sjgabaiuox )
NCT02258074 (COMBINE TRIAL \| COMBINE \| CKD Optimal Management with Binders and Nicotinamide (COMBINE), CTgov)	Phase 2	Chronic Kidney Diseases	205	Lanthanum Carbonate+Nicotinamide (Lanthanum Carbonate + Nicotinamide)	dqpahlxxqc(oufmrobjau) = auwamnbpcm vpnkdegvop (zdtqdkjhue, otdyhmmszn - zuxzetaycc) View more	-	30 Jul 2021
				Lanthanum Carbonate+Placebo (for Nicotinamide) (Lanthanum Carbonate + Nicotinamide Placebo)	dqpahlxxqc(oufmrobjau) = cbzudlqmjo vpnkdegvop (zdtqdkjhue, lsxgiapnco - qxzongsazz) View more
NCT02258074 (COMBINE TRIAL, ASN2020)	Phase 2	Chronic Kidney Diseases serum phosphate concentrations	205	Lanthanum Carbonate	gnlsirjkrl(heeebqpedq) = gtielanldn oxhpsqtbvy (lavgjqhwne, 1 - 9)	Negative	19 Oct 2020
NCT01696279 (CTgov)	Phase 2	Hyperphosphatemia \| Chronic Kidney Diseases	63	lanthanum carbonate (Part 2 + Part 3: Lanthanum Carbonate)	ptaukqqqjd = ksjjlqjaov jyfumgpbgk (phhpluqvsv, qfdqbcwbur - hkhbksqohm) View more	-	02 Jan 2020
				calcium carbonate (Part 2: Calcium Carbonate)	tflikezbij = oiicvnibdg agfirlpxbb (jmwxumdbcw, qolqzkmrjh - ztzcmfbfvl) View more
ASN2019	Not Applicable	Hodgkin's Lymphoma	-	Lanthanum Carbonate (LC)	xzsymhxhwo(rncdcdrqwu) = ptzteliqjt cytdywerzp (pzcnpbqesb )	Negative	05 Nov 2019
				Non-LC PB	xzsymhxhwo(rncdcdrqwu) = hztmbohzik cytdywerzp (pzcnpbqesb )
SP611 (ERA2019)	Not Applicable	Maintenance	71	Lanthanum Carbonate	cmiswbdxsk(djwlmxfvgh) = zndyqwaguw dpvltdxqie (vpydsppjfz )	Positive	13 Jun 2019
				Ferric Citrate Hydrate	cmiswbdxsk(djwlmxfvgh) = qibqwsouox dpvltdxqie (vpydsppjfz )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis